Theriva Biologics Announces First Patient Dosed in VIRAGE2 Trial

What Happened

• On August 6, 2026, Theriva Biologics, Inc. (TOVX) announced that the first patient was dosed in the VIRAGE2 clinical trial. VIRAGE2 is a small proof‑of‑concept study testing more frequent, repeated dosing of VCN‑01 (zabilugene almadenorepvec) in first‑line metastatic pancreatic ductal adenocarcinoma (PDAC) patients receiving standard‑of‑care gemcitabine/nab‑paclitaxel chemotherapy. Results from VIRAGE2 will be used to determine a dosing regimen for potential evaluation in a future pivotal Phase 3 trial.

Key Details

• Press release/8‑K date: August 6, 2026.
• Trial purpose: Evaluate more frequent repeated dosing of VCN‑01 in combination with gemcitabine/nab‑paclitaxel in first‑line metastatic PDAC.
• Timeline: Enrollment expected to complete in H2 2026; initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027.
• Clinical rationale: Based on VIRAGE Phase 2b data where two doses of VCN‑01 plus SoC chemotherapy showed improved overall survival, progression‑free survival, and duration of response versus SoC alone; EMA and FDA previously acknowledged those improved outcomes and suggested exploring more frequent dosing.

Why It Matters

• This is a clinical development milestone for Theriva: dosing the first patient starts the VIRAGE2 study that could define a dosing approach for a future Phase 3 trial. For investors, the main near‑term catalysts are enrollment completion (H2 2026) and initial safety/pharmacodynamic readout (Q3 2027).
• The trial builds on Phase 2b signals of improved survival with two doses of VCN‑01; positive VIRAGE2 results could support advancement toward a pivotal study, while negative or inconclusive results would raise program risk. The filing contains no financial data or guarantees of regulatory or commercial success.